We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Blood Test Predicts Response to Immunotherapy in Patients with Non-Small Cell Lung Cancer

By LabMedica International staff writers
Posted on 24 May 2022
Print article
Image: Blood-based tumor biomarker can predict immunotherapy benefit for NSCL Cancer (Photo courtesy of Northwestern University)
Image: Blood-based tumor biomarker can predict immunotherapy benefit for NSCL Cancer (Photo courtesy of Northwestern University)

Atezolizumab monotherapy, an immune checkpoint therapy, is an effective treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have high programmed death ligand 1 (PD-L1) expression. When PD-L1 is bound to the exterior of a cell, it tells roaming T-cells to leave the cell alone. Many cancers have upregulated PD-L1 to help hide cancer cells from the immune system. However, a biopsy is required to determine PD-L1 levels and as many as 30% of patients with NSCLC may not have enough high-quality tissue biopsied at diagnosis for accurate biomarker analyses. Now, a blood-based tumor biomarker can predict the benefits of immunotherapy to patients with NSCLC, according to a study.

In the trial, clinical scientists at the Northwestern University Feinberg School of Medicine (Chicago, IL, USA) enrolled 153 patients with NSCLC to analyze circulating tumor DNA (ctDNA) for tumor mutational burden (TMB), a measure of total mutations found in the DNA of cancer cells. Cancers with high TMB have been associated with a positive response to immune checkpoint inhibitor therapies. Of the patients, 28 had high TMB values - making them suitable for atezolizumab monotherapy - while 91 patients had low TMB values. Notably, the high TMB group was slightly younger and had more smokers. All patients received atezolizumab monotherapy, and response rates to the therapy were much higher in the high TMB group - 35.7% compared to just 5.5% in the low TMB group. Patients in the high TMB group also experienced longer survival than those in the low TMB group.

The findings demonstrate that measuring TMB in ctDNA is a viable option for stratifying patients for immune checkpoint inhibitor therapy, according to the investigators. While more work is required to understand the relationship between TMB and immune checkpoint inhibitor therapy - hopefully revealing a sub-population of patients who would benefit most from the therapy - the foundations for therapy selection using a simple blood test are strong,

“The findings from this study will help us identify and design better blood-based biomarkers in immuno-oncology,” said Young Kwang Chae, MD, MPH, MBA, associate professor of Medicine in the Division of Hematology and Oncology and a co-author of the study. “It will allow the right therapy to be delivered to the right group of patients.”

Related Links:
Northwestern University

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Quality Control Material
Multichem U
New
Gold Supplier
pHOx Analyzer
BioProfile pHOx Analyzer
New
Upright Laboratory Freezer
HLF125-GX

Print article

Channels

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.